EU court signals tough stance on ‘pay-for-delay’ pharma deals

Advocate general recommends upholding €60.48 million fine against Teva and Cephalon for anti-competitive modafinil settlement.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Mental health in IP: ‘We have a clear picture of the problem’

30 December 2025 The Life in the Law 2025 report sheds light on the mental health challenges faced by legal professionals, revealing the links between wellbeing, inclusion and modern working practices. IP Inclusive’s Andrea Brewster explores how the findings offer clear guidance for meaningful change.

Europe

From Edwards to Insulet: Three key medical device cases of 2025

29 December 2025 Edwards v Meril, Teva and the FTC, and modified jury verdicts—lawyers from WilmerHale provide a review of the key cases of the year and their implications.

Europe

Edwards v Meril: Behind the UPC’s landmark medtech showdown

24 December 2025 As Edwards secures another win against its rival, LSIPR talks to Siddharth Kusumakar—partner at Powell Gilbert and counsel for the winning party.

More features

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

WATCH: Clinical trials and their impact on patentability in Europe

EU court signals tough stance on ‘pay-for-delay’ pharma deals

More on this story

Editor's picks

Editor's picks

More features